Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival.

BACKGROUND A decade ago we reported the first use of laparoscopic radiofrequency thermal ablation (RFA) for the treatment of neuroendocrine hepatic metastases. This study analyzes our 10-year experience and determines characteristics predictive of survival. METHODS Eighty RFA sessions were performed in 63 patients with neuroendocrine hepatic metastases in a prospective trial. All patients had unresectable disease with computed tomography (CT) documented lesion and/or symptom progression. Perioperative morbidity, symptom relief, disease progression, and long-term survival were analyzed. Data are expressed as mean +/- standard error of the mean (SEM). RESULTS There were 22 women and 41 men, age 54.4 +/- 1.5 years followed for 2.8 +/- 0.3 years (range, 0.1 to 7.8). Tumor types included 36 carcinoid, 18 pancreatic islet cell, and 9 medullary thyroid cancer. RFA was performed 1.6 +/- 0.3 years after the diagnosis of liver metastases. Number of lesions treated was 6 +/- 0.5 (range, 1 to 16). Forty-nine patients underwent 1 ablation session, and 14 (22%) had repeat sessions caused by disease progression. Mean hospital stay was 1.1 days. Perioperative morbidity was 5%, with no 30-day mortality. Fifty-seven percent of patients exhibited symptoms. One week postoperatively 92% of these reported at least partial symptom relief, and 70% had significant or complete relief. Duration of symptom control was 11 +/- 2.3 months. CT follow-up demonstrated 6.3% local tumor recurrence. Larger dominant liver tumor size and male gender adversely impacted survival (P < .05). Median survival times were 11.0 years postdiagnosis of primary tumor, 5.5 years postdiagnosis of neuroendocrine hepatic metastases, and 3.9 years post-1st RFA. Survival for patients undergoing repeat ablation sessions was not significantly lower. CONCLUSIONS This study represents the largest series of neuroendocrine hepatic metastases treated by RFA. In this group of patients with aggressive neuroendocrine tumor metastases and limited treatment options, RFA provides effective local control with prompt symptomatic improvement.

[1]  S. Rogers,et al.  Predictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer , 2005, Surgical Endoscopy And Other Interventional Techniques.

[2]  C. Mussi,et al.  Gastrointestinal carcinoids. Prognosis and survival. , 2003, Minerva chirurgica.

[3]  B. Persson,et al.  Neuroendocrine metastases of the liver , 2004, World Journal of Surgery.

[4]  M. Clouse,et al.  Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. , 1994, Digestion.

[5]  K. Batts,et al.  Hepatic resection for metastatic neuroendocrine carcinomas. , 1995, American journal of surgery.

[6]  L. Kvols,et al.  Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. , 1986, The New England journal of medicine.

[7]  Y. Fong,et al.  Surgical resection of metastatic liver tumors. , 1996, Surgical oncology clinics of North America.

[8]  D. Morris,et al.  Cryotherapy for neuroendocrine liver metastases. , 1998, Seminars in surgical oncology.

[9]  D. Nagorney,et al.  Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. , 2003, Journal of the American College of Surgeons.

[10]  J. Ajani,et al.  The carcinoid syndrome: palliation by hepatic artery embolization. , 1986, AJR. American journal of roentgenology.

[11]  E. Berber,et al.  Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Pitt,et al.  Neuroendocrine Hepatic Metastases: Does Aggressive Management Improve Survival? , 2005, Annals of surgery.

[13]  M. Brennan,et al.  Prognostic variables in patients with gastrointestinal carcinoid tumours , 1994, The British journal of surgery.

[14]  S. Rogers,et al.  Laparoscopic radiofrequency ablation of primary and metastaticliver tumors , 2000, Surgical Endoscopy.

[15]  A. Giuliano,et al.  Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. , 1997, Surgery.

[16]  J. Seitz,et al.  Ultrasound‐guided percutaneous alcohol injection of small liver metastases. Results in 40 patients , 1994, Cancer.

[17]  R. Warren,et al.  Current management of colorectal liver metastases. , 2000, Surgical oncology clinics of North America.

[18]  C. Proye,et al.  Current Concepts in Functioning Endocrine Tumors of the Pancreas , 2004, World Journal of Surgery.

[19]  L. Kvols,et al.  Treatment of the Malignant Carcinoid Syndrome , 1987 .

[20]  E. Berber,et al.  Laparoscopic Radiofrequency Ablation of Neuroendocrine Liver Metastases , 2002, World Journal of Surgery.

[21]  K. Oberg,et al.  Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. , 1993, Acta oncologica.

[22]  A. Benson,et al.  Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. , 2001, Surgery.

[23]  K. Öberg.  Endocrine tumors of the gastrointestinal tract: systemic treatment. , 1994 .

[24]  L. Kvols,et al.  Chemotherapy of metastatic carcinoid and islet cell tumors. A review. , 1987, The American journal of medicine.

[25]  J. Norton,et al.  Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. , 1992, Surgery.

[26]  D. Morris,et al.  A collective review of the world literature on hepatic cryotherapy. , 1998, Journal of the Royal College of Surgeons of Edinburgh.

[27]  P. Ruszniewski,et al.  Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. , 2005, Best practice & research. Clinical gastroenterology.

[28]  K. Ahrar,et al.  Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors , 2005, Cancer.

[29]  R. Jian,et al.  Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. , 1996, Gut.

[30]  S. Rogers,et al.  Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. , 1997, Surgery.

[31]  C. Moertel.  Karnofsky memorial lecture. An odyssey in the land of small tumors. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  E. Berber,et al.  Cryoablation, Percutaneous Alcohol Injection, and Radiofrequency Ablation for Treatment of Neuroendocrine Liver Metastases , 2001, World Journal of Surgery.